Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial-Reference-Cited by-同舟云学术

Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial

Published:2017-01 Issue:1 Volume:144 Page:65-71
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Sorio Roberto,Roemer-Becuwe Célia,Hilpert Felix,Gibbs Emma,García Yolanda,Kaern Janne,Huizing Manon,Witteveen Petronella,Zagouri Flora,Coeffic David,Lück Hans-Joachim,González-Martín Antonio,Kristensen Gunnar,Levaché Charles-Briac,Lee Chee Khoon,Gebski Val,Pujade-Lauraine Eric

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference33 articles.

1. Why have ovarian cancer mortality rates declined? Part I. Incidence;Sopik;Gynecol. Oncol.,2015

2. Breast and ovarian cancer in the older woman;Tew;J. Clin. Oncol.,2014

3. EORTC elderly task force position paper: approach to the older cancer patient;Pallis;Eur. J. Cancer,2010

4. Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial;Falandry;Ann. Oncol.,2013

5. Treatment of elderly ovarian cancer patients in the context of controlled clinical trials: a joint analysis of the AGO Germany experience;Hilpert;Onkologie,2012

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial;Gynecologic Oncology;2024-08

2. Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer;Cancers;2024-07-25

3. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-07-05

4. Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022;Frontiers in Oncology;2023-05-18

5. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18